Latest News
Targovax ONCOS-102 trial in anti-PD1 refractory melanoma patients demonstrates best objective responses
2 December 2020 - Clinical stage immuno-oncology company Targovax ASA (OSE: TRVX), a developer of immune activators to target hard-to-treat solid tumours, declared on Tuesday that the combination of ONCOS-102 and pembrolizumab (Keytruda) has demonstr...
Ampio announces full open enrollment for AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients
2 December 2020 - Biopharmaceutical company Ampio Pharmaceuticals Inc (NYSE American: AMPE) disclosed on Wednesday that its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment, having been cleared b...
Italy plans to launch free COVID-19 vaccination programme in early 2021
2 December 2020 - Italy's Health Minister Roberto Speranza has stated that the country will launch a free coronavirus vaccination programme early in 2021, Reuters news agency reported on Wednesday.According to Speranza, the Italian government ha...
Genentech wins FDA approval of Xolair (omalizumab) for adults with nasal polyps
2 December 2020 - Biotechnology company Genentech reported on Tuesday the receipt of the US Food and Drug Administration's (FDA) supplemental Biologics License Application (sBLA) for Xolair (omalizumab) for the add-on maintenance treatment of na...
European Union's drug regulator considers longer approval process for COVID-19 vaccines to be safer
2 December 2020 - The drug regulator for the European Union has stated that its longer approval process for COVID-19 vaccines is safer, Reuters news agency reported on Wednesday.Emergency authorisation of Pfizer and BioNTech's COID-19 vaccine ha...